MedTrace Logo

An Efficacy and Safety Study of Rimonabant for Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients With Type 2 Diabetes

NCT00577148 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 89

Last updated 2016-05-18

No results posted yet for this study

Summary

The purpose of this study is to assess the effect of rimonabant treatment on the histological features of Nonalcoholic Steatohepatitis (NASH) in patients with Type 2 diabetes.

Conditions

Interventions

DRUG

Rimonabant

Tablet, oral administration

DRUG

Placebo (for Rimonabant)

Tablet, oral administration

Sponsors & Collaborators

Principal Investigators

  • ICD CSD · Sanofi

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2009-02-28
Completion
2009-02-28

Countries

  • United States
  • Argentina
  • Australia
  • Belgium
  • Brazil
  • Chile
  • China
  • Colombia
  • Croatia
  • France
  • Germany
  • Hungary
  • Italy
  • Malaysia
  • Mexico
  • Philippines
  • Poland
  • Portugal
  • Puerto Rico
  • Romania
  • Spain
  • Switzerland
  • Taiwan
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00577148 on ClinicalTrials.gov